ongterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
Phase 1
- Conditions
- Cerebral Adrenoleukodystrophy (CALD)MedDRA version: 20.0Level: PTClassification code: 10051260Term: Adrenoleukodystrophy Class: 100000004850MedDRA version: 20.0Level: SOCClassification code: 10010331Term: Congenital familial and genetic disorders Class: 21Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]
- Registration Number
- CTIS2024-513904-33-00
- Lead Sponsor
- Bluebird Bio Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Male
- Target Recruitment
- 64
Inclusion Criteria
Provision of written informed consent for this study by the subject or subject's parent(s)/ legal guardian(s) and written informed assent by subject, if applicable, Have received Lenti-D Drug Product in a parent clinical study.
Exclusion Criteria
There are no exclusion criteria for this Study.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method